Gliosarcoma — Trials · CancerIndex

Clinical trials

Registered studies

227 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 30
Recruiting: 12
Ph III recruiting: 0
Growth YoY: —
Industry share: 3%
Top sponsor: M.D. Anderson Cancer Center
Termination share: 43%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (55)

clinicaltrialsPublishedShowing 1–1 of 1 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT07422363	Testing the Combination of Anti-cancer Drugs Actimab-A and Cemiplimab (REGN2810) to Improve Outcomes for Patients With Recurrent Glioblastoma	not yet recruiting	Phase 1	30	National Cancer Institute (NCI)NIH	0	Jun 12, 2026	clinicaltrials

Data updated 22 days agoSource updated Jun 12, 2026source: clinicaltrials